A Phase I, Escalating Dose Study of VB6-845, a Recombinant Fusion Protein Targeting EpCAM, in Patients With Advanced Solid Tumours of Epithelial Origin
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2016
At a glance
- Drugs VB 6845 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Viventia Biotechnologies
- 09 Apr 2008 Status changed from recruiting to discontinued, as reported in ClinicalTrials.gov.
- 29 Jan 2008 Twelve patients have been enrolled to date.
- 25 Jun 2007 New trial record.